A Surgeon Just Operated In Apple Vision Pro.

Good morning, crowd. 

• A surgeon just used Apple Vision Pro to operate on a hip.

• Ray Kurzweil backed a brain interface you snort.

• IFA 2026 is unleashing robots and local AI.

• And Ultrahuman just proved smart rings can be AI controllers.

• Hardware isn't dead, it's accelerating.

In today's founders’ market intelligence:

Read time: 4 mins

Farmers Need Better Tools. Greenfield Is Building Them.

For generations, farmers have relied on bigger equipment and chemical inputs to improve productivity.

is building a new category of agricultural equipment: autonomous robots designed to help farmers manage weeds with precision.

But the bigger opportunity may be the platform itself. It raises a bigger question: if robots can autonomously manage weeds, what other farm tasks could they eventually take on?

Greenfield is already expanding the platform beyond weeding, with feeding, spraying, and cover-crop planting on the roadmap.

The vision: a new generation of farm equipment that can perform more work autonomously—potentially reducing dependence on chemical inputs and the rising costs associated with conventional farming.

Investors can own a stake in Greenfield Robotics through its Regulation A+ offering. Currently in Testing the Waters. .

^{Greenfield Robotics is Testing The Waters under tier 2 of Regulation A. No money or other consideration is being solicited, and if sent in response will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement filed by the company with the SEC has been qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the date of qualification. An indication of interest involves no obligation or commitment of any kind. “Reserving” shares is simply an indication of interest. There is no binding commitment for investors that reserve shares in this manner to ultimately invest and purchase the shares reserved of the company, or to purchase any shares of the company whatsoever.}

FRESH NEWS

Stryker

Deal DNA: A Duke Health surgeon used Apple's Vision Pro to operate on a hip while wearing the $3,499 headset. Stryker's app, the first FDA-authorized app for intraoperative Vision Pro use, pulled live arthroscopy video, CT scans, and surgical planning data into a single field of view. Translation: Vision Pro went from "expensive consumer tech" to "surgical tool worth buying."

The details:

• Duke Health: First intraoperative Vision Pro case (hip arthroscopy)

• App: Stryker's FDA De Novo authorization (July 17, 2026)

• Data consolidation: Live arthroscope feed + CT imaging + surgical planning in one view

• Competition: ClearSurgery (CE marking for cataract apps), ScopeXR (hundreds of cataract procedures)

• Market implication: If surgeons adopt Vision Pro, $3,499 price tag becomes ROI-positive (surgical efficiency > consumer price)

• Use case: Eliminates multi-screen switching during surgery (focus + accuracy)

• Regulatory signal: FDA greenlit spatial computing for intraoperative use (path cleared)

Why it matters: Vision Pro's mass-market identity was unclear ($3,499, limited consumer appeal). But in medicine, it's suddenly strategic. Every surgeon who can see live feeds + scans + planning data without looking away is a competitive advantage. This is how expensive hardware finds product-market fit: B2B use case + regulatory approval + ROI calculation. Vision Pro isn't a consumer flop—it's a $5B+ surgical tool waiting to scale.

Jose's take: Apple's strategy pivoting from consumer to B2B medtech is smart. Surgeons have budgets in millions. Hospitals care about outcomes, not price. Vision Pro's $3,499 becomes invisible when it improves surgery. This is the playbook: expensive hardware finds B2B first, scales to consumer second.

Ray

The Pattern: AI futurist Ray Kurzweil joined neurotech startup Subsense as advisor, backing an experimental brain-computer interface using nanoparticles snorted through the nose instead of permanent implants. Kurzweil's backing signals that non-invasive neural access is the future, not surgical implants.

The details:

• Subsense: Preclinical BCI using intranasal nanoparticles (read + stimulate neurons)

• Technology: Two types of nanoparticles (one reads signals, one stimulates) + external wearable

• Capital: $27M raised (early stage)

• Timeline: Clinical pilots 2027-29, no consumer BCI until 2031+

• Competitive advantage: No permanent electrodes, no surgery (vs. Neuralink, Synchron, Precision Neuroscience)

• Kurzweil's role: Product + vision advisor (legitimacy signal)

• Market opportunity: If intranasal delivery works, BCI adoption accelerates 10x

Why it matters: Neuralink's surgical implants are permanent, risky, and require medical procedures. Subsense's intranasal approach could be reversible, safer, and accessible. When Kurzweil (who predicted AI singularity in 2045) backs this, it signals: non-invasive neural interfaces are the next frontier. This competes directly with Neuralink's "permanent electrode" model. Winner: whoever gets non-invasive neural access to work reliably first.

Jose's take: Kurzweil backing intranasal BCIs over Neuralink's surgical implants shows the direction. Non-invasive > surgical. Reversible > permanent. If Subsense pulls it off, they're a $10B+ company. If they don't, Neuralink owns the market. Either way, neural interfaces are coming whether you like it or not.

Gizmodo

What's Actually Happening: IFA 2026 in Berlin showed a wave of experimental hardware: fanless sub-1cm laptops, solar-powered PCs, local-AI smart-home hubs, and increasingly ambitious household robots. Translation: Hardware isn't dying—it's getting smarter, thinner, and AI-powered.

The details:

• Lenovo AeroBlade: 14-inch OLED in sub-10mm body (solid-state AirJet cooling instead of fans)

• Oukitel Solar PC: 15W solar panels built into lid (charges 95Wh battery to 50% in 6 hours)

• Anker MindBase: Local AI hub for smart homes (runs AI on-device, not cloud-dependent)

• Dyson Robots: New Nurovi robot vacuums + floor cleaners expanding lineup

• CameraJet Toothbrush: Connected toothbrush (proof: everything gets smart)

• Trend: Thinner form factors + local AI processing + less cloud reliance

Why it matters: For years, we heard "hardware is dead, software is future." IFA 2026 says otherwise. Hardware + local AI is the new frontier. Every company is making their devices thinner, smarter on-device, and connected to AI locally. This reshapes the competitive moat: whoever gets local AI right (runs models on hardware, not cloud) wins the next decade. Cloud AI (OpenAI, Google) loses margin. Hardware makers (Lenovo, Dyson, Anker) gain margins.

Jose's take: IFA showed the future: hardware that runs AI locally, doesn't need cloud dependency, and gets thinner while staying powerful. Companies winning: those integrating AI into hardware. Companies losing: those betting on cloud-only. The PC revival just started.

Why Founders Care: Ultrahuman just raised $70M (Qualcomm Ventures leading) to pivot smart rings from health trackers into mini-computers. $365M valuation (3x from 2023). 800K rings sold. $140M ARR targeting $200M by January 2027. Meanwhile, Oura is IPO-ing with $1.2B revenue. Smart rings are becoming the wrist-worn AI controller everyone needs.

The details:

• Ultrahuman funding: $65M equity + $5M debt, $365M post-money valuation

• Qualcomm partnership: Co-developing ring using Qualcomm silicon (more processing power)

• Product roadmap: September update adds apps + games, exploring pointer/car key/gesture control

• Revenue: 800K rings sold, $140M annualized, targeting $200M by Jan 2027

• Market context: Oura IPO-ing at $1.2B revenue, 80%+ renewal, proving wearable subscription model works

• Competitive insight: If Ultrahuman hits $200M ARR, they're on track for $1B+ valuation by 2027

Why it matters: Oura proved wearables can scale to IPO. Ultrahuman just proved wearables can become AI controllers + payment devices + car keys. When Qualcomm gets involved, it means chip architecture is shifting: rings getting more processing power, not less. This is the evolution: rings went from "fitness tracker" (Fitbit) to "health tracker" (Oura) to "AI controller" (Ultrahuman). Next: rings as primary interface for apps + payments + AI interactions.

Jose's take: Ultrahuman's $365M valuation after $70M raise signals: smart rings are the next computing form factor. Smaller than a phone, always on, lower power consumption, close to the heart + neural signals. If Ultrahuman hits $200M ARR in 12 months, venture will value them at $1.5B+. Oura's IPO validates the category. Ultrahuman's funding validates the use case.

🚀 QUICK HITS: HARDWARE RENAISSANCE IN FULL SWING

🔬 Vision Pro Goes Surgical — Apple's $3,499 headset just found its billion-dollar market: operating rooms. One FDA approval leads to hospital adoption leads to $5B+ TAM. From consumer gadget to enterprise medical device in 18 months. Founder signal: expensive hardware finds B2B first, consumer second.

🧠 Brain Interfaces Go Intranasal — Ray Kurzweil backing Subsense signals the direction: non-invasive neural access (not surgical implants) is the next frontier. Neuralink owns permanent implants. Subsense could own reversible access. Competition shifts from "can we do it" to "invasive or non-invasive." Non-invasive wins.

💻 Local AI on Hardware Matters — Anker's MindBase (local smart home AI hub) shows the shift: cloud dependency becomes liability. Companies running AI on-device reduce latency, improve privacy, own the relationship. This year: cloud AI. Next year: hardware makers racing to embed AI locally.

☀️ Solar-Powered Computing — Oukitel's solar PC pulls 15W from built-in panels (charges battery to 50% in 6 hours). Proof that energy harvesting is now viable. Next: phones with solar, watches with solar, IoT devices with perpetual battery. Energy independence changes device design forever.

🤖 Household Robots Expanding — Dyson's new Nurovi vacuums + floor cleaners join existing robot lineups. Every consumer electronics company now has robotics division. Market: 100M+ homes globally. TAM: $100B+ by 2030. First movers (Dyson, iRobot, Ecovacs) own distribution.

🎮 Rings as Game Controllers — Ultrahuman exploring ring as gesture controller + app controller. Your hand becomes the interface. If rings run AI on-device, they become primary interface for AI interactions. No screen required. Just hand gestures + ring processing.

⌚ Payment Rings — Ultrahuman exploring ring as car key + payment device. Your ring becomes identity + wallet + key. Market: payments + access control = $10B+ TAM. Whoever owns "ring as primary payment method" owns wrist real estate.

📱 CameraJet Toothbrush — If you can put a camera in a toothbrush and connect it to AI, every household product becomes smart. Proof: the hardware renaissance includes everything.

🌐 Smart Home Decentralization — Anker MindBase running AI locally (not cloud) signals shift: privacy + performance > cloud convenience. Homes keeping data in-home becomes selling point. Cloud providers (Google, Amazon) need an on-device strategy or they lose margin.

🔌 Fanless Computing — Lenovo's sub-10mm laptop using solid-state AirJet cooling replaces traditional fans. Means: thinner, quieter, more reliable devices. Form factor revolution starting now.

☕ HERE'S WHAT TUESDAY SHOWS

Vision Pro finding killer app in medtech: Expensive hardware doesn't need mass market—it needs ROI Ray Kurzweil backing intranasal BCIs: Non-invasive neural access becomes competitive with surgical implants. IFA 2026 hardware renaissance: Local AI on hardware beats cloud-dependent models. Ultrahuman's $70M + Oura's IPO: Wearables moving from health tracking to AI controllers to payment devices

The pattern: Hardware is back. AI is the fuel. Local processing is the moat. Wearables are the next computing frontier.

☕ HUNT ACCORDINGLY

If you're building hardware: Add AI locally (not cloud-dependent). You own the relationship.

If you're building wearables: Think AI controller first, health tracker second. Ultrahuman proved the direction.

If you're building medical devices: Vision Pro's surgical success shows high-price B2B medical devices with good ROI are fundable. Don't chase consumer price points.

If you're building neural interfaces: Intranasal delivery (non-invasive) is winning the narrative over surgical implants. Kurzweil said so.

See you soon,

Jose, Alberto, and the Founderscrowd editorial team